Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 6
2003 11
2004 11
2005 9
2006 10
2007 10
2008 4
2009 7
2010 12
2011 12
2012 11
2013 13
2014 23
2015 15
2016 17
2017 16
2018 17
2019 10
2020 48
2021 68
2022 57
2023 48
2024 28
2025 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

444 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: MAVDA
Page 1
Mitochondrial hyperactivity and reactive oxygen species drive innate immunity to the yellow fever virus-17D live-attenuated vaccine.
Muccilli SG, Schwarz B, Shue B, Jessop F, Shannon JG, Larson CL, Hage A, Hong SH, Bohrnsen E, Hsu T, Ashbrook AW, Sturdevant GL, Robertson SJ, Guarnieri JW, Lack J, Wallace DC, Bosio CM, MacDonald MR, Rice CM, Yewdell JW, Best SM. Muccilli SG, et al. Among authors: rice cm. PLoS Pathog. 2025 Apr 21;21(4):e1012561. doi: 10.1371/journal.ppat.1012561. eCollection 2025 Apr. PLoS Pathog. 2025. PMID: 40258014 Free PMC article.
The yellow fever virus 17D (YFV-17D) live attenuated vaccine is considered one of the most successful vaccines ever generated associated with high antiviral immunity, yet the signaling mechanisms that drive the response in infected cells are not understood. ...
The yellow fever virus 17D (YFV-17D) live attenuated vaccine is considered one of the most successful vaccines ever generated associated wit …
Enhanced TLR7-dependent production of type I interferon by pDCs underlies pandemic chilblains.
Saidoune F, Lee D, Di Domizio J, Le Floc'h C, Jenelten R, Le Pen J, Bondet V, Joncic A, Morren MA, Béziat V, Zhang SY, Jouanguy E, Duffy D, Rice CM, Conrad C, Fellay J, Casanova JL, Gilliet M, Yatim A. Saidoune F, et al. Among authors: rice cm. J Exp Med. 2025 Jul 7;222(7):e20231467. doi: 10.1084/jem.20231467. Epub 2025 Apr 14. J Exp Med. 2025. PMID: 40227192 Free PMC article.
Outbreaks of chilblains were reported during the COVID-19 pandemic. Given the essential role of type I interferon (I-IFN) in protective immunity against SARS-CoV-2 and the association of chilblains with inherited type I interferonopathies, we hypothesized that excessive I- …
Outbreaks of chilblains were reported during the COVID-19 pandemic. Given the essential role of type I interferon (I-IFN) in protecti …
Antibody evasiveness of SARS-CoV-2 subvariants KP.3.1.1 and XEC.
Wang Q, Guo Y, Mellis IA, Wu M, Mohri H, Gherasim C, Valdez R, Purpura LJ, Yin MT, Gordon A, Ho DD. Wang Q, et al. Among authors: ho dd. Cell Rep. 2025 Apr 22;44(4):115543. doi: 10.1016/j.celrep.2025.115543. Epub 2025 Apr 8. Cell Rep. 2025. PMID: 40202847 Free PMC article.
Rapid luminescence-based screening method for SARS- CoV-2 inhibitors discovery.
Madani A, Alvarez N, Park S, Murugan M, Perlin DS. Madani A, et al. Among authors: perlin ds. SLAS Discov. 2025 Mar;31:100211. doi: 10.1016/j.slasd.2025.100211. Epub 2025 Jan 15. SLAS Discov. 2025. PMID: 39824441 Free article.
The COVID-19 pandemic has emphasized the necessity for rapid and adaptable drug screening platforms against live pathogenic viruses that require high levels of biosafety containment. Conventional antiviral testing is time-consuming and labor-intensive. Here, we outl …
The COVID-19 pandemic has emphasized the necessity for rapid and adaptable drug screening platforms against live pathogenic viruses t …
A multiplex method for rapidly identifying viral protease inhibitors.
Hong SJ, Resnick SJ, Iketani S, Cha JW, Albert BA, Fazekas CT, Chang CW, Liu H, Dagan S, Abagyan MR, Fajtová P, Culbertson B, Brace B, Reddem ER, Forouhar F, Glickman JF, Balkovec JM, Stockwell BR, Shapiro L, O'Donoghue AJ, Sabo Y, Freundlich JS, Ho DD, Chavez A. Hong SJ, et al. Among authors: chavez a, ho dd, sabo y, glickman jf, shapiro l. Mol Syst Biol. 2025 Feb;21(2):158-172. doi: 10.1038/s44320-024-00082-1. Epub 2025 Jan 6. Mol Syst Biol. 2025. PMID: 39762652 Free PMC article.
Development of small molecule non-covalent coronavirus 3CL protease inhibitors from DNA-encoded chemical library screening.
Liu H, Zask A, Forouhar F, Iketani S, Williams A, Vaz DR, Habashi D, Choi K, Resnick SJ, Hong SJ, Lovett DH, Bai T, Chavez A, Ho DD, Stockwell BR. Liu H, et al. Among authors: chavez a, ho dd. Nat Commun. 2025 Jan 2;16(1):152. doi: 10.1038/s41467-024-55421-5. Nat Commun. 2025. PMID: 39747827 Free PMC article.
With a binding mode different from the covalent 3CL inhibitor nirmatrelvir, the protease inhibitor in the COVID drug Paxlovid, these compounds may overcome resistance reported for nirmatrelvir and complement its clinical utility....
With a binding mode different from the covalent 3CL inhibitor nirmatrelvir, the protease inhibitor in the COVID drug Paxlovid, these …
A common form of dominant human IFNAR1 deficiency impairs IFN-α and -ω but not IFN-β-dependent immunity.
Al Qureshah F, Le Pen J, de Weerd NA, Moncada-Velez M, Materna M, Lin DC, Milisavljevic B, Vianna F, Bizien L, Lorenzo L, Lecuit M, Pommier JD, Keles S, Ozcelik T, Pedraza-Sanchez S, de Prost N, El Zein L, Hammoud H, Ng LFP, Halwani R, Saheb Sharif-Askari N, Lau YL, Tam AR, Singh N, Bhattad S, Berkun Y, Chantratita W, Aguilar-López R, Shahrooei M; COVID-19 HGE Consortium; SEAe Consortium; Abel L, Bastard P, Jouanguy E, Béziat V, Zhang P, Rice CM, Cobat A, Zhang SY, Hertzog PJ, Casanova JL, Zhang Q. Al Qureshah F, et al. Among authors: rice cm. J Exp Med. 2025 Feb 3;222(2):e20241413. doi: 10.1084/jem.20241413. Epub 2024 Dec 16. J Exp Med. 2025. PMID: 39680367 Free PMC article.
Small-molecule inhibition of SARS-CoV-2 NSP14 RNA cap methyltransferase.
Meyer C, Garzia A, Miller MW, Huggins DJ, Myers RW, Hoffmann HH, Ashbrook AW, Jannath SY, Liverton N, Kargman S, Zimmerman M, Nelson AM, Sharma V, Dolgov E, Cangialosi J, Penalva-Lopez S, Alvarez N, Chang CW, Oswal N, Gonzalez I, Rasheed R, Goldgirsh K, Davis JA, Ramos-Espiritu L, Menezes MR, Larson C, Nitsche J, Ganichkin O, Alwaseem H, Molina H, Steinbacher S, Glickman JF, Perlin DS, Rice CM, Meinke PT, Tuschl T. Meyer C, et al. Among authors: rice cm, glickman jf, perlin ds, tuschl t. Nature. 2025 Jan;637(8048):1178-1185. doi: 10.1038/s41586-024-08320-0. Epub 2024 Dec 11. Nature. 2025. PMID: 39663451
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)(1). The rapid development of highly effective vaccines(2,3) against SARS-CoV-2 has altered the trajectory of the pandemic, and antiviral therapeutics(4) hav …
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)(1). The rapid developme …
444 results